Recent Advances in Neuroinflammation Therapeutics: PPARs/LXR as Neuroinflammatory Modulators

Author(s): Sussy Bastias-Candia, Nicolas Garrido A., Juan M. Zolezzi, Nibaldo C. Inestrosa

Journal Name: Current Pharmaceutical Design

Volume 22 , Issue 10 , 2016

Become EABM
Become Reviewer
Call for Editor


Neurodegenerative disorders are one of the most critical public health concerns of our times. Regrettably, therapeutic interventions currently available have shown only partial benefits to patients affected by one of these disorders. Although the important advances made during the last decades, several questions regarding physiopathological aspects of these diseases are still open. On this regard, the role of neuroinflammation is recognized as critical during the establishment and progression of the neurodegenerative process, and several authors have suggested that neuroinflammatory modulation should be at the basis of therapeutic treatment. In the present review we summarize the general aspects of the neuroinflammatory process and the cellular component of such response whose have been commonly related with the main neurodegenerative disorders, particularly Alzheimer’s and Parkinson’s disease, as well as, the main molecular events that might trigger the inflammatory process and affect neuronal support structures, such as the blood brain barrier, leading to neurodegeneration. Additionally, we discuss recent advances regarding Nuclear Receptors research, such as peroxisome proliferators-activated receptors and liver X receptor, and the molecular basis of its potential role against neuroinflammation and neurodegeneration.

Keywords: Neurodegeneration, chronic inflammation, inflammatory mediators, glial activation, nuclear receptors.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 04 March, 2016
Page: [1312 - 1323]
Pages: 12
DOI: 10.2174/1381612822666151223103038
Price: $65

Article Metrics

PDF: 45
PRC: 4